S&P 500   3,748.93 (-0.52%)
DOW   30,861.62 (-0.20%)
QQQ   300.40 (-1.22%)
AAPL   118.15 (-1.65%)
MSFT   228.22 (+0.66%)
FB   257.53 (-0.04%)
GOOGL   2,047.68 (+0.68%)
TSLA   565.00 (-9.08%)
AMZN   2,918.01 (-2.00%)
NVDA   475.85 (-3.83%)
BABA   229.55 (-0.41%)
CGC   29.02 (-6.42%)
GE   13.36 (-1.55%)
MU   85.17 (+1.00%)
NIO   32.23 (-17.95%)
AMD   75.67 (-2.68%)
T   29.39 (+1.63%)
F   11.82 (-0.92%)
ACB   8.98 (-8.55%)
DIS   185.35 (-1.43%)
BA   216.76 (-3.54%)
NFLX   505.39 (-1.15%)
BAC   36.34 (-0.44%)
S&P 500   3,748.93 (-0.52%)
DOW   30,861.62 (-0.20%)
QQQ   300.40 (-1.22%)
AAPL   118.15 (-1.65%)
MSFT   228.22 (+0.66%)
FB   257.53 (-0.04%)
GOOGL   2,047.68 (+0.68%)
TSLA   565.00 (-9.08%)
AMZN   2,918.01 (-2.00%)
NVDA   475.85 (-3.83%)
BABA   229.55 (-0.41%)
CGC   29.02 (-6.42%)
GE   13.36 (-1.55%)
MU   85.17 (+1.00%)
NIO   32.23 (-17.95%)
AMD   75.67 (-2.68%)
T   29.39 (+1.63%)
F   11.82 (-0.92%)
ACB   8.98 (-8.55%)
DIS   185.35 (-1.43%)
BA   216.76 (-3.54%)
NFLX   505.39 (-1.15%)
BAC   36.34 (-0.44%)
S&P 500   3,748.93 (-0.52%)
DOW   30,861.62 (-0.20%)
QQQ   300.40 (-1.22%)
AAPL   118.15 (-1.65%)
MSFT   228.22 (+0.66%)
FB   257.53 (-0.04%)
GOOGL   2,047.68 (+0.68%)
TSLA   565.00 (-9.08%)
AMZN   2,918.01 (-2.00%)
NVDA   475.85 (-3.83%)
BABA   229.55 (-0.41%)
CGC   29.02 (-6.42%)
GE   13.36 (-1.55%)
MU   85.17 (+1.00%)
NIO   32.23 (-17.95%)
AMD   75.67 (-2.68%)
T   29.39 (+1.63%)
F   11.82 (-0.92%)
ACB   8.98 (-8.55%)
DIS   185.35 (-1.43%)
BA   216.76 (-3.54%)
NFLX   505.39 (-1.15%)
BAC   36.34 (-0.44%)
S&P 500   3,748.93 (-0.52%)
DOW   30,861.62 (-0.20%)
QQQ   300.40 (-1.22%)
AAPL   118.15 (-1.65%)
MSFT   228.22 (+0.66%)
FB   257.53 (-0.04%)
GOOGL   2,047.68 (+0.68%)
TSLA   565.00 (-9.08%)
AMZN   2,918.01 (-2.00%)
NVDA   475.85 (-3.83%)
BABA   229.55 (-0.41%)
CGC   29.02 (-6.42%)
GE   13.36 (-1.55%)
MU   85.17 (+1.00%)
NIO   32.23 (-17.95%)
AMD   75.67 (-2.68%)
T   29.39 (+1.63%)
F   11.82 (-0.92%)
ACB   8.98 (-8.55%)
DIS   185.35 (-1.43%)
BA   216.76 (-3.54%)
NFLX   505.39 (-1.15%)
BAC   36.34 (-0.44%)
Log in
NASDAQ:CRON

Cronos Group Stock Forecast, Price & News

$9.04
-0.60 (-6.22 %)
(As of 03/5/2021 11:45 AM ET)
Add
Compare
Today's Range
$8.67
Now: $9.04▼
$9.74
50-Day Range
$9.91
MA: $11.41▼
$15.55
52-Week Range
$4.00
Now: $9.04▼
$15.83
Volume390,938 shs
Average Volume7.92 million shs
Market Capitalization$3.26 billion
P/E Ratio37.67
Dividend YieldN/A
Beta2.07
Cronos Group Inc. operates as a cannabinoid company in the United States and internationally. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through ecommerce, retail, and hospitality partner channels. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. Its brand portfolio includes PEACE NATURALS, a global wellness platform; adult-use brands comprise COVE and Spinach; and hemp-derived CBD brands consists of Lord Jones and PEACE+. Cronos Group Inc. is based in Toronto, Canada.
Cronos Group logo

Headlines

Cronos Stock Pulls Back After Earnings, It Might Be Time To Buy Some
February 26, 2021 |  marketbeat.com
Cronos Group: Slow Launch
March 1, 2021 |  seekingalpha.com
Cronos Group Inc. (CRON) CEO Kurt Schmidt on Q4 2020 Results - Earnings Call Transcript
February 28, 2021 |  seekingalpha.com
Cronos Group Inc. (CRON) Reports 2020 Fourth Quarter and Full-Year Results
February 27, 2021 |  marketwatch.com
Cronos Group Inc. (CRON) Q4 2020 Earnings Call Transcript
February 26, 2021 |  fool.com
Cannabis Stocks Skid On Cronos Earnings, But Industry Poised For Growth
February 26, 2021 |  forbes.com
Cronos Group Slides on Q4 Results
February 26, 2021 |  finance.yahoo.com
Cronos Group (CRON) Reports Q4 Loss, Tops Revenue Estimates
February 26, 2021 |  nasdaq.com
Cronos Drops After Cannabis Firm Swings to Quarterly Loss
February 26, 2021 |  msn.com
Wall Street Analysts Advise Selling These 2 Cannabis Stocks
February 24, 2021 |  stocknews.com
TSX rises 0.2% to 18,422.24
February 22, 2021 |  msn.com
Stay Away from These 4 Overvalued Marijuana Stocks
February 22, 2021 |  stocknews.com
Interesting CRON Put And Call Options For April 1st
February 13, 2021 |  nasdaq.com
IIROC Trading Halt - CRON
February 12, 2021 |  finance.yahoo.com
IIROC Trade Resumption - CRON
February 12, 2021 |  finance.yahoo.com
Cronos Group Inc. to Hold 2020 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2021
February 12, 2021 |  finance.yahoo.com
TSX Closes Higher
February 11, 2021 |  marketwatch.com
Sundial, Tilray, Aphria Continue Rally Amid High Retail Investor Interest
February 11, 2021 |  benzinga.com
CANADA STOCKS - TSX rises 0.16% to 18,438.73
February 11, 2021 |  nasdaq.com
Big Marijuana: Tobacco Giant Altria Is Pushing Cannabis Policy On Congress And State Lawmakers
February 9, 2021 |  forbes.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRON
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.thecronosgroup.com
Phone416-504-0004
Employees631
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio9.75
Quick Ratio9.36

Price-To-Earnings

Trailing P/E Ratio37.67
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.64 million
Price / Sales127.02
Cash Flow$0.61 per share
Price / Cash Flow14.76
Book Value$5.01 per share
Price / Book1.80

Profitability

EPS (Most Recent Fiscal Year)$0.67
Net Income$1.17 billion
Net Margins266.31%
Return on Equity-1.61%
Return on Assets-1.41%

Miscellaneous

Outstanding Shares360,257,000
Market Cap$3.26 billion
Next Earnings Date5/14/2021 (Estimated)
OptionableOptionable

MarketRank™

Overall MarketRank™

0.65 out of 5 stars

Medical Sector

1271st out of 1,969 stocks

Medicinals & Botanicals Industry

15th out of 33 stocks

Analyst Opinion: 0.9Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$9.04
-0.60 (-6.22 %)
(As of 03/5/2021 11:45 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRON News and Ratings via Email

Sign-up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cronos Group (NASDAQ:CRON) Frequently Asked Questions

Is Cronos Group a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Cronos Group stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRON, but not buy additional shares or sell existing shares.
View analyst ratings for Cronos Group or view top-rated stocks.

What stocks does MarketBeat like better than Cronos Group?

Wall Street analysts have given Cronos Group a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cronos Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cronos Group's next earnings date?

Cronos Group is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Cronos Group.

How were Cronos Group's earnings last quarter?

Cronos Group Inc. (NASDAQ:CRON) released its quarterly earnings data on Thursday, February, 25th. The company reported ($0.31) EPS for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.25. The company had revenue of $17.05 million for the quarter, compared to analysts' expectations of $17.35 million. Cronos Group had a negative trailing twelve-month return on equity of 1.61% and a net margin of 266.31%. The business's revenue for the quarter was up 133.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) EPS.
View Cronos Group's earnings history.

How has Cronos Group's stock been impacted by Coronavirus (COVID-19)?

Cronos Group's stock was trading at $5.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRON shares have increased by 71.2% and is now trading at $9.26.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CRON?

8 brokers have issued twelve-month price targets for Cronos Group's stock. Their forecasts range from $5.00 to $12.50. On average, they anticipate Cronos Group's share price to reach $8.56 in the next year. This suggests that the stock has a possible downside of 7.5%.
View analysts' price targets for Cronos Group or view top-rated stocks among Wall Street analysts.

Who are Cronos Group's key executives?

Cronos Group's management team includes the following people:
  • Mr. Michael Ryan Gorenstein, Exec. Chairman (Age 34, Pay $333.57k)
  • Mr. Jerry Filomena Barbato, Chief Financial Officer (Age 45, Pay $299.63k)
  • Ms. Xiuming Shum, Exec. VP of Legal and Regulatory Affairs & Corp. Sec. (Age 35, Pay $190.18k)
  • Mr. Kurt Thomas Schmidt B.Sc., M.B.A., Pres & CEO (Age 64)
  • Mr. Shayne J. Laidlaw, Director of Investor Relations & Strategy
  • Ms. Shannon Buggy, Sr. VP & Global Head of People
  • Ms. Anna Shlimak, Sr. VP of Corp. Affairs (Age 35)
  • Dr. Todd K. Abraham, Chief Innovation Officer (Age 66)
  • Puneet Mathur, VP & Controller
  • Ms. Summer Frein, Gen. Mang. of USA (Age 37)

Who are some of Cronos Group's key competitors?

Some companies that are related to Cronos Group include Canopy Growth (CGC), STADA Arzneimittel Aktiengesellschaft (STDAF), Aphria (APHA), Tilray (TLRY), USANA Health Sciences (USNA), Aurora Cannabis (ACB), Sundial Growers (SNDL), HEXO (HEXO), ChromaDex (CDXC), Canopy Rivers (RIV), Charlie's (CHUC), MediWound (MDWD), Natural Alternatives International (NAII), Nutra Pharma (NPHC) and Glucose Health (GLUC).
View all of CRON's competitors.

What other stocks do shareholders of Cronos Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include (CGC), Aurora Cannabis (ACB), Tilray (TLRY), (APHA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Dollar Tree (DLTR), Micron Technology (MU), Alibaba Group (BABA) and OrganiGram (OGI).

What is Cronos Group's stock symbol?

Cronos Group trades on the NASDAQ under the ticker symbol "CRON."

Who are Cronos Group's major shareholders?

Cronos Group's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ETF Managers Group LLC (2.07%), Morgan Stanley (0.15%), Public Sector Pension Investment Board (0.14%), Swiss National Bank (0.12%), BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp (0.08%) and Vontobel Holding Ltd. (0.07%). Company insiders that own Cronos Group stock include Jason Marc Adler, Michael Ryan Gorenstein and Todd Kevin Abraham.
View institutional ownership trends for Cronos Group.

Which institutional investors are selling Cronos Group stock?

CRON stock was sold by a variety of institutional investors in the last quarter, including Swiss National Bank, Mackenzie Financial Corp, State of Wisconsin Investment Board, Toronto Dominion Bank, Seven Eight Capital LP, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, The Manufacturers Life Insurance Company , and Hsbc Holdings PLC. Company insiders that have sold Cronos Group company stock in the last year include Jason Marc Adler, and Michael Ryan Gorenstein.
View insider buying and selling activity for Cronos Group or view top insider-selling stocks.

Which institutional investors are buying Cronos Group stock?

CRON stock was bought by a variety of institutional investors in the last quarter, including Vontobel Holding Ltd., Morgan Stanley, ETF Managers Group LLC, Voloridge Investment Management LLC, Virtu Financial LLC, Dynamic Technology Lab Private Ltd, Penserra Capital Management LLC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Cronos Group or or view top insider-buying stocks.

How do I buy shares of Cronos Group?

Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cronos Group's stock price today?

One share of CRON stock can currently be purchased for approximately $9.26.

How much money does Cronos Group make?

Cronos Group has a market capitalization of $3.34 billion and generates $25.64 million in revenue each year. The company earns $1.17 billion in net income (profit) each year or $0.67 on an earnings per share basis.

How many employees does Cronos Group have?

Cronos Group employs 631 workers across the globe.

What is Cronos Group's official website?

The official website for Cronos Group is www.thecronosgroup.com.

Where are Cronos Group's headquarters?

Cronos Group is headquartered at 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9.

How can I contact Cronos Group?

Cronos Group's mailing address is 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9. The company can be reached via phone at 416-504-0004.


This page was last updated on 3/5/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.